Experience
Coherus Biosciences, Inc.
AbbVie Biotechnology, Ltd.
Finnegan client AbbVie Inc. fended off multiple petitions filed by biosimilar developer Coherus Biosciences, seeking inter partes review (IPR) of a patent related to certain formulations of adalimumab, the antibody in AbbVie’s anti-inflammatory drug Humira®. The Patent Trial and Appeal Board (PTAB) issued four decisions, each denying institution and holding that Coherus failed to demonstrate a reasonable likelihood of prevailing at trial as to the unpatentability of any challenged claim.
Coherus Biosciences, Inc. v. AbbVie Biotechnology, Ltd., IPR2017-00822, -00823, -01008, -01009, PTAB, Judges Ankenbrand, Hulse, Mitchell
Carnegie Institution of Washington et al. v. Pure Grown Diamonds, Inc. et al.
Pure Grown Diamonds, Inc. et al.
Bright Data Ltd. v. NetNut Ltd.
NetNut Ltd.
Delta Faucet Company v. Globe Union Industrial Corp. et al.
Globe Union Industrial Corp.
Hawk Technology Systems, LLC v. Kirkland's Inc.
Kirkland's Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Rondevoo Technologies, LLC v. RSIP Vision, Inc.
RSIP Vision, Inc.
Eureka Database Solutions, LLC v. Nexidia, Inc.
Nexidia, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.